Bridgefront Capital LLC lifted its holdings in Centene Co. (NYSE:CNC - Free Report) by 149.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,459 shares of the company's stock after buying an additional 6,272 shares during the quarter. Bridgefront Capital LLC's holdings in Centene were worth $634,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in CNC. Capital Advisors Ltd. LLC lifted its position in shares of Centene by 75.3% during the fourth quarter. Capital Advisors Ltd. LLC now owns 412 shares of the company's stock worth $25,000 after purchasing an additional 177 shares in the last quarter. Hurley Capital LLC bought a new position in Centene in the 4th quarter valued at $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Centene in the 4th quarter valued at $30,000. OFI Invest Asset Management bought a new stake in shares of Centene during the fourth quarter worth $33,000. Finally, SRS Capital Advisors Inc. lifted its stake in shares of Centene by 73.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 631 shares of the company's stock valued at $38,000 after acquiring an additional 267 shares during the period. Institutional investors and hedge funds own 93.63% of the company's stock.
Centene Stock Up 0.6 %
NYSE CNC traded up $0.40 during trading on Friday, hitting $62.82. The stock had a trading volume of 4,416,347 shares, compared to its average volume of 4,812,148. The company's 50-day moving average price is $60.53 and its two-hundred day moving average price is $60.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.10 and a current ratio of 1.11. The company has a market capitalization of $31.26 billion, a PE ratio of 10.07, a P/E/G ratio of 0.80 and a beta of 0.48. Centene Co. has a 12 month low of $55.03 and a 12 month high of $80.59.
Centene (NYSE:CNC - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.52 by $0.38. Centene had a return on equity of 13.85% and a net margin of 2.03%. The company had revenue of $46.62 billion during the quarter, compared to analysts' expectations of $43.16 billion. During the same period last year, the firm posted $2.26 earnings per share. The business's revenue was up 15.4% on a year-over-year basis. As a group, sell-side analysts forecast that Centene Co. will post 6.86 EPS for the current year.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. Argus cut Centene from a "buy" rating to a "hold" rating in a report on Thursday, February 6th. StockNews.com lowered shares of Centene from a "strong-buy" rating to a "buy" rating in a report on Monday, April 28th. Jefferies Financial Group dropped their target price on shares of Centene from $64.00 to $61.00 and set a "hold" rating for the company in a research report on Tuesday, April 29th. Robert W. Baird reduced their price target on Centene from $71.00 to $69.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 15th. Finally, Guggenheim reissued a "neutral" rating on shares of Centene in a research note on Tuesday, April 29th. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, Centene currently has an average rating of "Moderate Buy" and a consensus price target of $79.77.
View Our Latest Stock Report on Centene
About Centene
(
Free Report)
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support.
Further Reading
Before you consider Centene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centene wasn't on the list.
While Centene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
